中关村：盐酸丁螺环酮片一致性评价申报获受理

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets [1] Group 1: Company Developments - Beijing Huasu has received the acceptance notice for the application of Buprenorphine Hydrochloride Tablets (specifications: 5mg, 10mg) [1] - The drug Buprenorphine is the first non-benzodiazepine anxiolytic, acting as a 5-HT1A receptor agonist [1] Group 2: Drug Characteristics - Buprenorphine works by selectively binding to the brain's 5-HT1A receptors, reducing excessive 5-HT activity associated with anxiety disorders [1] - The main clinical advantage of Buprenorphine is its lack of drug dependence and withdrawal reactions, indicating a higher safety profile [1] - The indications for Buprenorphine Hydrochloride Tablets include various anxiety disorders [1]